Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BrightSpring Health Services (BTSG) Cash & Equivalents (2023 - 2025)

BrightSpring Health Services' Cash & Equivalents history spans 3 years, with the latest figure at $88.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 44.98% year-over-year to $88.4 million; the TTM value through Dec 2025 reached $88.4 million, up 44.98%, while the annual FY2025 figure was $88.4 million, 44.98% up from the prior year.
  • Cash & Equivalents reached $88.4 million in Q4 2025 per BTSG's latest filing, down from $140.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $140.3 million in Q3 2025 to a low of $13.1 million in Q4 2023.
  • Average Cash & Equivalents over 3 years is $60.5 million, with a median of $58.0 million recorded in 2024.
  • Peak YoY movement for Cash & Equivalents: soared 366.33% in 2024, then dropped 9.82% in 2025.
  • A 3-year view of Cash & Equivalents shows it stood at $13.1 million in 2023, then skyrocketed by 366.33% to $61.0 million in 2024, then surged by 44.98% to $88.4 million in 2025.
  • Per Business Quant, the three most recent readings for BTSG's Cash & Equivalents are $88.4 million (Q4 2025), $140.3 million (Q3 2025), and $70.1 million (Q2 2025).